331 related articles for article (PubMed ID: 28342224)
1. Interleukin-18 activates Vγ9Vδ2
Murday AS; Chaudhry S; Pauza CD
Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
[TBL] [Abstract][Full Text] [Related]
2. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
5. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
6. Antigen-presenting effects of effector memory Vγ9Vδ2 T cells in rheumatoid arthritis.
Hu C; Qian L; Miao Y; Huang Q; Miao P; Wang P; Yu Q; Nie H; Zhang J; He D; Xu R; Chen X; Liu B; Zhang D
Cell Mol Immunol; 2012 May; 9(3):245-54. PubMed ID: 22139198
[TBL] [Abstract][Full Text] [Related]
7. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
[TBL] [Abstract][Full Text] [Related]
8. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.
Casetti R; Perretta G; Taglioni A; Mattei M; Colizzi V; Dieli F; D'Offizi G; Malkovsky M; Poccia F
J Immunol; 2005 Aug; 175(3):1593-8. PubMed ID: 16034098
[TBL] [Abstract][Full Text] [Related]
10. Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells.
Dunne MR; Mangan BA; Madrigal-Estebas L; Doherty DG
Mediators Inflamm; 2010; 2010():704941. PubMed ID: 21403900
[TBL] [Abstract][Full Text] [Related]
11. Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations.
Nerdal PT; Peters C; Oberg HH; Zlatev H; Lettau M; Quabius ES; Sousa S; Gonnermann D; Auriola S; Olive D; Määttä J; Janssen O; Kabelitz D
J Immunol; 2016 Oct; 197(8):3059-3068. PubMed ID: 27619996
[TBL] [Abstract][Full Text] [Related]
12. Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines.
Poccia F; Battistini L; Cipriani B; Mancino G; Martini F; Gougeon ML; Colizzi V
J Infect Dis; 1999 Sep; 180(3):858-61. PubMed ID: 10438380
[TBL] [Abstract][Full Text] [Related]
13. Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons.
Boullier S; Poquet Y; Debord T; Fournie JJ; Gougeon ML
Eur J Immunol; 1999 Jan; 29(1):90-9. PubMed ID: 9933090
[TBL] [Abstract][Full Text] [Related]
14. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
15. Skewed representation of functionally distinct populations of Vgamma9Vdelta2 T lymphocytes in aging.
Re F; Poccia F; Donnini A; Bartozzi B; Bernardini G; Provinciali M
Exp Gerontol; 2005; 40(1-2):59-66. PubMed ID: 15664733
[TBL] [Abstract][Full Text] [Related]
16. IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.
Moens E; Brouwer M; Dimova T; Goldman M; Willems F; Vermijlen D
J Leukoc Biol; 2011 May; 89(5):743-52. PubMed ID: 21330350
[TBL] [Abstract][Full Text] [Related]
17. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
[TBL] [Abstract][Full Text] [Related]
18. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
[TBL] [Abstract][Full Text] [Related]
19. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
[TBL] [Abstract][Full Text] [Related]
20. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
